{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:42:04Z","timestamp":1771306924952,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A large proportion of the world\u2019s disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.<\/jats:p>","DOI":"10.1007\/s11096-023-01643-4","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:02:08Z","timestamp":1695812528000},"page":"1286-1292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5909-6930","authenticated-orcid":false,"given":"Matej","family":"Stuhec","sequence":"first","affiliation":[]},{"given":"M.","family":"Hahn","sequence":"additional","affiliation":[]},{"given":"I.","family":"Taskova","sequence":"additional","affiliation":[]},{"given":"I.","family":"Bayraktar","sequence":"additional","affiliation":[]},{"given":"I.","family":"Fitzgerald","sequence":"additional","affiliation":[]},{"given":"L.","family":"Molitschnig","sequence":"additional","affiliation":[]},{"given":"A.","family":"Tatarevi\u0107","sequence":"additional","affiliation":[]},{"given":"N.","family":"Lindner","sequence":"additional","affiliation":[]},{"given":"L.","family":"Agnoletto","sequence":"additional","affiliation":[]},{"given":"F. Alves","family":"da Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"1643_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137\u201350.","journal-title":"Lancet Psychiatry"},{"key":"1643_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1643_CR3","unstructured":"World mental health report: transforming mental health for all; 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240049338. Accessed 15 May 2023."},{"issue":"10312","key":"1643_CR4","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700\u201312.","journal-title":"Lancet"},{"key":"1643_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1017\/S0033291717003336","volume":"48","author":"S Evans-Lacko","year":"2018","unstructured":"Evans-Lacko S, Aguilar-Gaxiola S, Al-Hamzawi A, et al. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. Psychol Med. 2018;48:1560\u201371.","journal-title":"Psychol Med"},{"key":"1643_CR6","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095\u2013105.","journal-title":"JAMA"},{"key":"1643_CR7","unstructured":"Depression in adults: treatment and management. NICE guideline [NG222]. Published: 29 June 2022. https:\/\/www.nice.org.uk\/guidance\/ng222\/chapter\/Update-information. Accessed 15 May 2023."},{"key":"1643_CR8","unstructured":"European Society of Clinical Pharmacy (ESCP). https:\/\/escpweb.org\/. Accessed 15 Aug 2023."},{"key":"1643_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/YCO.0000000000000808","volume":"35","author":"M Stuhec","year":"2022","unstructured":"Stuhec M. Antipsychotic treatment in elderly patients on polypharmacy with schizophrenia. Curr Opin Psychiatry. 2022;35:332\u20137.","journal-title":"Curr Opin Psychiatry"},{"key":"1643_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.genhosppsych.2009.05.011","volume":"31","author":"M Smolders","year":"2009","unstructured":"Smolders M, Laurant M, Verhaak P, et al. Adherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis. Gen Hosp Psychiatry. 2009;31:460\u20139.","journal-title":"Gen Hosp Psychiatry"},{"key":"1643_CR11","doi-asserted-by":"publisher","first-page":"204512532110110","DOI":"10.1177\/20451253211011007","volume":"11","author":"M Stuhec","year":"2021","unstructured":"Stuhec M, Lah L. Clinical pharmacist interventions in elderly patients with mental disorders in primary care focused on psychotropics: a retrospective pre-post observational study. Ther Adv Psychopharmacol. 2021;11:20451253211011010.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1643_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00406-017-0798-6","volume":"267","author":"DP Herzog","year":"2017","unstructured":"Herzog DP, Wagner S, Ruckes C, et al. Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2017;267:711\u201321.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1643_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/13651501.2011.638142","volume":"16","author":"S K\u00f6hler","year":"2012","unstructured":"K\u00f6hler S, Hoffmann S, Unger T, et al. Adherence to guidelines and effectiveness of inpatient treatment for unipolar depression. Int J Psychiatry Clin Pract. 2012;16:103\u201312.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1643_CR14","doi-asserted-by":"publisher","first-page":"11387","DOI":"10.1038\/s41598-022-15657-x","volume":"12","author":"M Stuhec","year":"2022","unstructured":"Stuhec M, Zorjan K. Clinical pharmacist interventions in ambulatory psychogeriatric patients with excessive polypharmacy. Sci Rep. 2022;12:11387.","journal-title":"Sci Rep"},{"key":"1643_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/CIA.S192252","volume":"14","author":"JP Aguiar","year":"2019","unstructured":"Aguiar JP, Heitor Costa L, Alves da Costa F, et al. Identification of potentially inappropriate medications with risk of major adverse cardiac and cerebrovascular events among elderly patients in ambulatory setting and long-term care facilities. Clin Interv Aging. 2019;14:535\u201347.","journal-title":"Clin Interv Aging"},{"key":"1643_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","volume":"5","author":"ER Hajjar","year":"2007","unstructured":"Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345\u201351.","journal-title":"Am J Geriatr Pharmacother"},{"key":"1643_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/pds.3592","volume":"23","author":"S Dechanont","year":"2014","unstructured":"Dechanont S, Maphanta S, Butthum B, et al. Hospital admissions\/visits associated with drug\u2013drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489\u201397.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1643_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/jcpt.12811","volume":"44","author":"JP Aguiar","year":"2019","unstructured":"Aguiar JP, Brito AM, Martins AP, et al. Potentially inappropriate medications with risk of cardiovascular adverse events in the elderly: a systematic review of tools addressing inappropriate prescribing. J Clin Pharm Ther. 2019;44:349\u201360.","journal-title":"J Clin Pharm Ther"},{"key":"1643_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12913-019-3942-3","volume":"19","author":"M Stuhec","year":"2019","unstructured":"Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Serv Res. 2019;19:118.","journal-title":"BMC Health Serv Res"},{"key":"1643_CR20","doi-asserted-by":"publisher","first-page":"809.e1","DOI":"10.1016\/j.jamda.2017.06.003","volume":"18","author":"B Janssens","year":"2017","unstructured":"Janssens B, Petrovic M, Jacquet W, et al. Medication use and its potential impact on the oral health status of nursing home residents in Flanders (Belgium). J Am Med Dir Assoc. 2017;18:809.e1-809.e8.","journal-title":"J Am Med Dir Assoc"},{"key":"1643_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s00508-013-0342-2","volume":"125","author":"E Mann","year":"2013","unstructured":"Mann E, Haastert B, B\u00f6hmdorfer B, et al. Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents: secondary analysis of a cross-sectional study. Wien Klin Wochenschr. 2013;125:180\u20138.","journal-title":"Wien Klin Wochenschr"},{"key":"1643_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","volume":"169","author":"HC Kales","year":"2012","unstructured":"Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169:71\u20139.","journal-title":"Am J Psychiatry"},{"key":"1643_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2020.03.022","volume":"35","author":"JP Aguiar","year":"2020","unstructured":"Aguiar JP, Alves da Costa F, Egberts T, et al. The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: a case\/non-case study using VigiBase. Eur Neuropsychopharmacol. 2020;35:30\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1643_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eurpsy.2017.01.002","volume":"42","author":"M Stuhec","year":"2017","unstructured":"Stuhec M, Locatelli I. Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: a population-based study. Eur Psychiatry. 2017;42:129\u201333.","journal-title":"Eur Psychiatry"},{"key":"1643_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen J, Taipale H, Meht\u00e4l\u00e4 J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiat. 2019;76:499\u2013507.","journal-title":"JAMA Psychiat"},{"key":"1643_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","volume":"19","author":"H Taipale","year":"2020","unstructured":"Taipale H, Tanskanen A, Meht\u00e4l\u00e4 J, et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19:61\u20138.","journal-title":"World Psychiatry"},{"key":"1643_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380.","journal-title":"Schizophr Res"},{"key":"1643_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481\u20135.","journal-title":"Br J Psychiatry"},{"key":"1643_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4088\/JCP.v64n0107","volume":"64","author":"DM Taylor","year":"2003","unstructured":"Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64:30\u20134.","journal-title":"J Clin Psychiatry"},{"key":"1643_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia (Heidelberg). 2022;8:5.","journal-title":"Schizophrenia (Heidelberg)"},{"key":"1643_CR31","first-page":"PCC.11m01324","volume":"14","author":"JF Farley","year":"2012","unstructured":"Farley JF, Hansen RA, Yu-Isenberg KS, et al. Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. Prim Care Companion CNS Disord. 2012;14:PCC.11m01324.","journal-title":"Prim Care Companion CNS Disord."},{"key":"1643_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","volume":"70","author":"L Wunderink","year":"2013","unstructured":"Wunderink L, Nieboer RM, Wiersma D, et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiat. 2013;70:913\u201320.","journal-title":"JAMA Psychiat"},{"key":"1643_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.24869\/psyd.2017.155","volume":"29","author":"CB Bole","year":"2017","unstructured":"Bole CB, Pi\u0161lar M, Mrhar A, et al. Prescribing patterns for inpatients with schizophrenia spectrum disorders in a psychiatric hospital in Slovenia: results of 16-month prospective, non-interventional clinical research. Psychiatr Danub. 2017;29:155\u201361.","journal-title":"Psychiatr Danub"},{"key":"1643_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0924-9338(99)80713-5","volume":"14","author":"H Rittmannsberger","year":"1999","unstructured":"Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry. 1999;14:33\u201340.","journal-title":"Eur Psychiatry"},{"key":"1643_CR35","doi-asserted-by":"publisher","first-page":"885216","DOI":"10.3389\/fpsyt.2022.885216","volume":"13","author":"JP Aguiar","year":"2022","unstructured":"Aguiar JP, Gama Marques J, Leufkens HGM, et al. Healthcare professionals\u2019 views on the management of medication complexities in the elderly with mental health disorders: a cross-sectional study. Front Psychiatry. 2022;13:885216.","journal-title":"Front Psychiatry"},{"key":"1643_CR36","doi-asserted-by":"publisher","first-page":"604201","DOI":"10.3389\/fpsyt.2020.604201","volume":"11","author":"JP Aguiar","year":"2020","unstructured":"Aguiar JP, Bernardo C, Gama Marques J, et al. Identification of a set of patient-related features to foster safe prescribing of specific antipsychotics in the elderly with dementia. Front Psychiatry. 2020;11:604201.","journal-title":"Front Psychiatry"},{"key":"1643_CR37","first-page":"158","volume":"56","author":"A Virani","year":"2003","unstructured":"Virani A, Crown N. The impact of a clinical pharmacist on patient and economic outcomes in a child and adolescent mental health. Can J Hosp Pharm. 2003;56:158\u201362.","journal-title":"Can J Hosp Pharm"},{"key":"1643_CR38","doi-asserted-by":"publisher","first-page":"e010003","DOI":"10.1136\/bmjopen-2015-010003","volume":"6","author":"AB Mekonnen","year":"2016","unstructured":"Mekonnen AB, McLachlan AJ, Brien JA. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016;6:e010003.","journal-title":"BMJ Open"},{"key":"1643_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/pharmacy9030146","volume":"9","author":"H Javelot","year":"2021","unstructured":"Javelot H, Gitahy Falcao Faria C, Vandenberghe F, et al. Clinical pharmacy in psychiatry: towards promoting clinical expertise in psychopharmacology. Pharmacy (Basel). 2021;9:146.","journal-title":"Pharmacy (Basel)"},{"key":"1643_CR40","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1592\/phco.23.15.1634.31952","volume":"23","author":"PR Finley","year":"2003","unstructured":"Finley PR, Crismon ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy. 2003;23:1634\u201344.","journal-title":"Pharmacotherapy"},{"key":"1643_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11096-013-9900-y","volume":"36","author":"TE Richardson","year":"2014","unstructured":"Richardson TE, O\u2019Reilly CL, Chen TF. A comprehensive review of the impact of clinical pharmacy services on patient outcomes in mental health. Int J Clin Pharm. 2014;36:222\u201332.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.9740\/mhc.2022.01.015","volume":"12","author":"C Gillespie","year":"2022","unstructured":"Gillespie C, Kleinberg F, Zogas A, et al. Perceptions of clinical pharmacy specialists\u2019 contributions in mental health clinical teams. Ment Health Clin. 2022;12:15\u201322.","journal-title":"Ment Health Clin"},{"key":"1643_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1331\/JAPhA.2011.09147","volume":"51","author":"PR Finley","year":"2011","unstructured":"Finley PR, Bluml BM, Bunting BA, et al. Clinical and economic outcomes of a pilot project examining pharmacist-focused collaborative care treatment for depression. J Am Pharm Assoc. 2011;51:40\u20139.","journal-title":"J Am Pharm Assoc"},{"key":"1643_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1592\/phco.23.10.1175.32760","volume":"23","author":"PR Finley","year":"2003","unstructured":"Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial. Pharmacotherapy. 2003;23:1175\u201385.","journal-title":"Pharmacotherapy"},{"key":"1643_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.genhosppsych.2003.08.005","volume":"26","author":"DA Adler","year":"2004","unstructured":"Adler DA, Bungay KM, Wilson IB, et al. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. Gen Hosp Psychiatry. 2004;26:199\u2013209.","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"1643_CR46","doi-asserted-by":"publisher","first-page":"16856","DOI":"10.1038\/s41598-019-53057-w","volume":"9","author":"M Stuhec","year":"2019","unstructured":"Stuhec M, Bratovi\u0107 N, Mrhar A. Impact of clinical pharmacist\u2019s interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: a prospective non-randomized study. Sci Rep. 2019;9:16856.","journal-title":"Sci Rep"},{"key":"1643_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/s-0032-1332831","volume":"40","author":"M Hahn","year":"2013","unstructured":"Hahn M, Reiff J, Hiemke C, et al. Arzneimittelinteraktionen in der Psychiatrie [Drug\u2013drug-interactions in psychiatry]. Psychiatr Prax. 2013;40:154\u20138.","journal-title":"Psychiatr Prax"},{"key":"1643_CR48","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s11096-019-00897-1","volume":"41","author":"E Buist","year":"2019","unstructured":"Buist E, McLelland R, Rushworth GF, et al. An evaluation of mental health clinical pharmacist independent prescribers within general practice in remote and rural Scotland. Int J Clin Pharm. 2019;41:1138\u201342.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR49","doi-asserted-by":"publisher","first-page":"13641","DOI":"10.1038\/s41598-021-92909-2","volume":"11","author":"M Stuhec","year":"2021","unstructured":"Stuhec M, Tement V. Positive evidence for clinical pharmacist interventions during interdisciplinary rounding at a psychiatric hospital. Sci Rep. 2021;11:13641.","journal-title":"Sci Rep"},{"key":"1643_CR50","first-page":"393","volume":"16","author":"JL G\u00f6ren","year":"2010","unstructured":"G\u00f6ren JL, Beck SE, Mills BJ, et al. Development and delivery of a quality improvement program to reduce antipsychotic polytherapy. J Manag Care Pharm. 2010;16:393\u2013401.","journal-title":"J Manag Care Pharm"},{"key":"1643_CR51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.9740\/mhc.2016.09.242","volume":"6","author":"A Gunterus","year":"2016","unstructured":"Gunterus A, Lopchuk S, Dunn C, et al. Quantitative and economic analysis of clinical pharmacist interventions during rounds in an acute care psychiatric hospital. Ment Health Clin. 2016;6:242\u20137.","journal-title":"Ment Health Clin"},{"key":"1643_CR52","first-page":"24","volume":"9","author":"M Hahn","year":"2012","unstructured":"Hahn M, Roll SC. A new approach to pharmaceutical care: experiences with the \u201cEichberger\u201d Model in a psychiatric clinic in Germany. Drug Ther perspect. 2012;9:24\u20136.","journal-title":"Drug Ther perspect"},{"key":"1643_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.9740\/mhc.2022.06.193","volume":"12","author":"G Spann","year":"2022","unstructured":"Spann G, Austin L, King E. Pharmacists in clozapine clinics improving physical health monitoring. Ment Health Clin. 2022;12:193\u20138.","journal-title":"Ment Health Clin"},{"issue":"6","key":"1643_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.9740\/mhc.2020.11.358","volume":"10","author":"A Werremeyer","year":"2020","unstructured":"Werremeyer A, Bostwick J, Cobb C, et al. Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders. Ment Health Clin. 2020;10:358\u201380.","journal-title":"Ment Health Clin"},{"key":"1643_CR55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11096-021-01321-3","volume":"44","author":"L Moura","year":"2022","unstructured":"Moura L, Steurbaut S, Salvesen Blix H, et al. A cross-sectional survey to map Clinical Pharmacy Education and Practice in Europe. Int J Clin Pharm. 2022;44:118\u201326.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR56","unstructured":"Committee of Ministers Resolution CM\/Res(2020)3 on the Implementation of Pharmaceutical Care for the Benefit of Patients and Health Services. https:\/\/go.edqm.eu\/ResPhCare20203. Accessed 22 Apr 2023."},{"key":"1643_CR57","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1007\/s11096-021-01306-2","volume":"43","author":"M Stuhec","year":"2021","unstructured":"Stuhec M. Clinical pharmacist consultant in primary care settings in Slovenia focused on elderly patients on polypharmacy: successful national program from development to reimbursement. Int J Clin Pharm. 2021;43:1722\u20137.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11096-022-01492-7","volume":"45","author":"M Schulz","year":"2023","unstructured":"Schulz M, Griese-Mammen N, M\u00fcller U. Clinical pharmacy services are reimbursed in Germany: challenges of real world implementation remain. Int J Clin Pharm. 2023;45:245\u20139.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR59","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11096-022-01422-7","volume":"44","author":"T Dreischulte","year":"2022","unstructured":"Dreischulte T, van den Bemt B, Steurbaut S, European Society of Clinical Pharmacy. European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care: a position paper. Int J Clin Pharm. 2022;44:837\u201342.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR60","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11096-021-01319-x","volume":"43","author":"F Alves da Costa","year":"2021","unstructured":"Alves da Costa F, Stewart D. Universal health coverage for mental health: the contribution of clinical pharmacists. Int J Clin Pharm. 2021;43:1153\u20134.","journal-title":"Int J Clin Pharm"},{"key":"1643_CR61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1310\/hpj4802-112","volume":"48","author":"SB Smith","year":"2013","unstructured":"Smith SB, Mango MD. Pharmacy-based medication reconciliation program utilizing pharmacists and technicians: a process improvement initiative. Hosp Pharm. 2013;48:112\u20139.","journal-title":"Hosp Pharm"},{"key":"1643_CR62","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.18549\/PharmPract.2020.3.2043","volume":"18","author":"N Ribeiro","year":"2020","unstructured":"Ribeiro N, Mota-Filipe H, Guerreiro MP, et al. Primary health care policy and vision for community pharmacy and pharmacists in Portugal. Pharm Pract (Granada). 2020;18:2043.","journal-title":"Pharm Pract (Granada)"},{"key":"1643_CR63","unstructured":"Declaration of Astana. World Health Organisation. https:\/\/www.who.int\/docs\/default-source\/primary-health\/declaration\/gcphc-declaration.pdf. Accessed 15 May 2023."},{"key":"1643_CR64","unstructured":"Networking and collaboration: American Association of Psychiatric Pharmacists. https:\/\/aapp.org\/. Accessed 15 May 2023."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01643-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T14:10:17Z","timestamp":1698243017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01643-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01643-4","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Filipa Alves da Costa\u00a0is the an associate editor of the International Journal of Clinical Pharmacy. She\u00a0had no role in handling the manuscript, specifically the processes of editorial review, peer review and decision making.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}